Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Apricus Biosciences, Inc. (Nasdaq: APRI) Partner Gains Mexico Approval

Apricus Biosciences, Inc. – Nasdaq: APRI

Shares of Apricus Biosciences shot up on news that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction. Shares, traded on the Nasdaq under ticker symbol APRI, ended Tuesday at $1.51 for the micro-cap drug manufacturer and have been as high as $3.77 in early trading.

This is the twenty-sixth country in which the product has been approved. Richard Pascoe, Chief Executive Officer of Apricus stated in a press release We are very pleased that Ferring has received its second approval for Vitaros in Latin America. Moreover, we look forward to Ferring’s launches of Vitaros in Latin America throughout the year, in addition to the portfolio of countries across the EU they have the rights to as well. Again, congratulations to the Ferring team for their continued commitment to building the Vitaros global brand.”

In 2015 APRI EPS lost $3.83 on sales of $4.8 million. Two firms follow Apricus Biosciences, Inc. One rates APRI shares as a “Buy” the other rates APRI as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/18/2017
Ticker Symbol GIMO
Last Price a/o 11:06 AM EST  $                      3.33
Average Volume 261,650
Market Cap $12.25 million
Sales $8 million
Shares Outstanding 8.11 million
Share Float 6.8 million
Shortable Yes
Optionable Yes
Inside Ownership 5.00%
Short Float 3.69%
Short Interest Ratio 0.96
Quarterly Return -52.81%
YTD Return 16.15%
Year Return -88.38%

Gigamon Inc. (Nasdaq: GIMO) Provides Lower Guidance – Shares Dive

Gigamon, Inc. – Nasdaq: GIMO

Gigamon shares plunged in after-hours trading by over 20% after the company provided guidance that was below expectations. Traded on the Nasdaq under ticker GIMO, the shares ended the regular session at $44.05. However news of revenues coming in between $84 and $84.5 million in contrast to prior guidance of $92.2 million sent the shares to a after-hours low of $33.50.

Gigamon provides active visibility into physical and virtual network traffic enabling stronger security and superior performance. Gigamon’s Visibility Fabric™ and GigaSECURE®, the industry’s first Security Delivery Platform, deliver advanced intelligence so that security, network and application performance management solutions in enterprise, government and service provider networks operate more efficiently and effectively. With over ten years’ experience, Gigamon solutions are deployed globally across vertical markets including over seventy-five percent of the Fortune 100.

Eight firms follow Gigamon Inc. and three of those rate GIMO as a “Strong Buy”, one rates GIMO a “Buy”, and three rate GIMO a “Hold”. GIMO’s consensus price target is $58.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol GIMO
Last Price a/o 6:06 PM EST  $                    34.65
Average Volume 833,900
Market Cap $1.59 Billion
Sales $292.9 million
Shares Outstanding 36.05 million
Share Float 32.36 million
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 9.08%
Short Interest Ratio 3.52
Quarterly Return -11.26%
YTD Return -3.29%
Year Return 96.21%

Progress Software Corporation (Nasdaq: PRGS) Tumbles After Disappointing Earnings, Revenues

Progress Software Corporation – Nasdaq: PRGS

The market expressed its disappointment in the reported earnings and revenue announcement of Progress Software Corporation by selling shares of PRGS and sending the stock gapping down on the open. PRGS ended Friday at $32.25 but opened Tuesday at $29.46. PRGS continued to come under pressure through the trading day and ended at $27.63.

Progress Software Corporation provides business software solutions for various industries worldwide. Chief Executive Officer Yogesh Gupta said in a release “I am pleased with our earnings per share and adjusted free cash flow performance during the quarter despite revenue falling short of our goals. Initiatives undertaken during the quarter to manage our expenses allowed us to reach this outcome. I am excited by the opportunities we have in front of us, and look forward to what we can accomplish in 2017 and beyond.”

Analysts had expected EPSof $0.62 but Progress Software reported $0.56. Similarly, expectations of $124 million in revenues were met with a figure of $118. Three firms cover PRGS with one rating it a “Strong Buy” and the other two rate PRGS as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol PRGS
Last Price a/o 3:53 PM EST  $                    27.62
Average Volume 200,000
Market Cap $1.54 Billion
Sales $40.3 million
Shares Outstanding 47.7 million
Share Float 47.34 million
Shortable Yes
Optionable Yes
Inside Ownership 1.50%
Short Float 1.54%
Short Interest Ratio 3.66
Quarterly Return 19.86%
YTD Return 1.00%
Year Return 29.49%

 

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Tandem Diabetes Inc. (Nasdaq: TNDM) Up >15% in Mid-Day Trading

Tandem Diabetes Care, Inc. – Nasdaq: TNDM

San Diego, CA-based Tandem Diabetes Care, Inc. shares are up over 15% in mid-day trading. The shares, traded on the Nasdaq under ticker symbol TNDM, closed Friday at $2.40 and have reached as high as $2.85 on heavy volumes.

Tandem Diabetes Care, Inc. designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set.

Sales have been consistently higher year-on-year. In 2012 Tandem Diabetes reported sales of $2.5 million and in 2015 they reported sales of $72.9 million. However, EPS for TNDM shares have not been so easy on the eyes. In 2011 Tandem Diabetes Inc. reported and EPS loss of $1.24. In 2013, there was a whopping $21.46 loss, but in 2015 Tandem Diabetes narrowed the loss to $2.50. Eleven firms follow Tandem Diabetes Inc and five rate TNDM as a “Strong Buy”, one rates the shares a “Buy” four rate TNDM as a “Hold”, and one rates TNDM as an “Underperform”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol TNDM
Last Price a/o 1:41 PM EST  $                      2.78
Average Volume 550,000
Market Cap $67.4 million
Sales $84.5 million
Shares Outstanding 28.08 million
Share Float 20.44 million
Shortable Yes
Optionable Yes
Inside Ownership 32.00%
Short Float 9.26%
Short Interest Ratio 3.46
Quarterly Return -65.76%
YTD Return 11.63%
Year Return -70.19%

Benitec Biopharma Limited (Nasdaq: BNTC) Secures EU Exclusivity

Benitec Biopharma Limited – Nasdaq: BNTC

Benitec Biopharma Limited shares are up over 75% from their Friday close of $1.85. The Australian company trades on the Nasdaq as an American Depository Share (ADR) under ticker BNTC. Investors seem to be responding to news that the European Union designated Benitech Biopharma’s BB-301 as an Orphan Drug for the treatment of oculopharyngeal muscular dystrophy. The designation of Benitec’s drug as an Orphan drug carries with it a 10-year exclusivity for the EU market.

Benitec Biopharma is a biotechnology company developing a therapeutic technology platform that combines gene silencing and gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. The company belives their technology has the potential to be a “one shot” cure for a wide range of diseases that are currently addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. Using proprietary technology, Benitec is developing a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases. They expect a Phase 1 and 2 study to begin in 2018.

The single firm that follows Benitec Biopharma Limited rates shares of BNTC as a “Hold”. As of this writing, BNTC has no reported EPS and sales of $7 million.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Kindred BioSciences (Nasdaq: KIN) Hits Yearly High on Heavy Volume

Kindred BioSciences Inc. – Nasdaq: KIN

Kindred BioSciences Inc. is a biotechnology firm that leverages the R&D funding of human pharmaceuticals by re-purposing existing human drugs for the pet market. Traded on the Nasdaq under ticker KIN, the shares are trading, on heavy volume, today at their highest point in over a year – $6.30.

Based in Burlingame, CA, Kindred Bioscience’s stated mission is to bring pets the same kind of innovative, breakthrough medicines that humans have access to. Kindred Bioscience is one of the first pet biotechs in the world, and has a world-class team, including the former Director of FDA’s Center for Veterinary Medicine and the former Head of Biotherapeutics Clinical Research at Genentech. They hope to arbitrage the differences in the market size for human pharmaceuticals (about 10 times larger than for pets) and the expense for developing those pharmaceuticals (about 100 times less).

Kindred Biosciences has no reported sales and KIN has never experienced positive EPS. However, KIN is rated as a “Strong Buy” by the only two analysts that cover the shares.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/13/2017
Ticker Symbol KIN
Last Price a/o 12:27 PM EST  $                      6.23
Average Volume 82,000
Market Cap $113.5 million
Sales
Shares Outstanding 19.74 million
Share Float 17.17 million
Shortable Yes
Optionable Yes
Inside Ownership 15.97%
Short Float 0.23%
Short Interest Ratio 0.48
Quarterly Return 10.58%
YTD Return 35.29%
Year Return 74.77%
Smart Sand Inc (NASDAQ:SND)

Magellan Petroleum Corporation (Nasdaq: MPET) Up Despite Lawsuit Threat

Magellan Petroleum Corporation – Nasdaq: MPET

Despite the threat of a lawsuit being brought against Magellan Petroleum and its Board of Directors, shares have risen over the past two days. MPET, traded on the Nasdaq, On January 10 the shares began trading around $5, on January 11 the New York firm of Monteverde & Associates PC announced an investigation into Magellan, and MPET ended at $13.20 on January 12.

According to a press release, the investigation focuses on whether Magellan and/or its Board of Directors violated federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by 1) failing to properly value the merger and 2) failing to disclose all material information in connection with the merger. Under the terms of the agreement, Tellurian Investments common stockholders will receive 1.30 shares of Magellan common stock for each share of Tellurian Investments common stock that they hold immediately prior to the effective time of the merger. The merger was valued at $207 million.

Magellan Petroleum has reported negative EPS since 2013 when it reported a loss of $2.83 EPS. In 2016 Magellan reported a narrower loss of $0.17. Magellan Petroleum has no reported sales for 2015 and 2016. Only one firm follows Magellan Petroleum and rates shares of MEPT as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Neuroderm Ltd. (Nasdaq: NDRM) Posting Near Highs Despite Index Drop

NeuroDerm Ltd. – Nasdaq: NDRM

Israeli-based Neuroderm Ltd. was dropped from the Nasdaq Biotechnology Index in December yet shares have rebounded from the subsequent sell-off amidst heavy volumes. The shares, traded on the Nasdaq under ticker NDRM, are last at $23.45 – the highest they have traded since September of 2015.

NeuroDerm is a clinical-stage pharmaceutical company developing treatments for central nervous system disorders designed to make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

Five firms follow Neuroderm Ltd. Four give NDRM a “Strong Buy” rating and one rates NDRM as a “Buy”. Their consensus price target is $30. Neuroderm Ltd. has no reported sales and gas never posted positive EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/12/2017
Ticker Symbol NDRM
Last Price a/o 1:38 PM EST  $                    22.85
Average Volume 151,000
Market Cap $532 million
Sales
Shares Outstanding 25.5 million
Share Float 15.14 million
Shortable Yes
Optionable Yes
Inside Ownership 52.73%
Short Float 4.72%
Short Interest Ratio 4.71
Quarterly Return 14.84%
YTD Return -5.86%
Year Return 45.04%

Century Aluminum (Nasdaq: CENX) Up on WTO Complaint Reports

Century Aluminum Company – Nasdaq: CENX

Reports that the U.S. may launch formal complaints with the World Trade Organization against Chinese aluminum producers sent shares of Century Aluminum (Nasdaq: CENX) up at least 10% in early trading. The U.S. intends, according to reports, to accuse China of providing below-market financing to Chinese aluminum companies that allowed them to modernize their plants and expand production. Also, allegedly in the complaint, are accusations that the Chinese aluminum producers were sold energy, in the form of coal and electricity, at below-market rates.

Chicago, IL-based Century Aluminum Company is a global producer of aluminum and operates aluminum reduction facilities in the United States and Iceland. Century Aluminum owns three U.S. aluminum smelters, in Hawesville, Kentucky, Robards, Kentucky and Mt. Holly, South Carolina, and one smelter in Grundartangi, Iceland. In 2008, Century Aluminum began construction on an aluminum reduction facility in Helguvik, Iceland, construction of which is currently delayed.

Four firms follow Century Aluminum Company and all rate shares of CENX as a “Hold”. CENX is currently trading above its consensus price target of $7.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/12/2017
Ticker Symbol CENX
Last Price a/o 10:13 AM EST  $                    10.01
Average Volume 2 million
Market Cap $809 million
Sales $1.36 Billion
Shares Outstanding 90 million
Share Float 49.3 million
Shortable Yes
Optionable Yes
Inside Ownership 43.00%
Short Float 23.31%
Short Interest Ratio 5.63
Quarterly Return 20.51%
YTD Return 5.02%
Year Return 201.68%